Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication due to their ability to transfer bioactive lipids, proteins and different species of RNA into cells. Thus, EVs hold therapeutic potential in their own right and can additionally be harnessed for the delivery of macromolecular drugs. This presentation will cover the developments in producing, purifying and characterizing engineered EVs. Strategies to engineer producer cells in order to generate EVs harboring selected proteins for treatment of inflammatory diseases will be discussed. In particular, the concept of displaying decoy receptors or antibodies that act as extracellular scavengers or intracellular effectors will be described in greater detail. Finally, the challenges in production and scalable purification of these EVs will be outlined.